The goal of the Protocol Review and Monitoring System (PRMS) is to promote the conduct of scientifically meritorious clinical research under the aegis of the UCSD Moores (iancer Center. The mechanism for accomplishing this goal is the establishment of a Protocol Review and Monitoring Committee (PRMC) to provide internal oversight of all clinical and translational research involving subjects with cancer. The PRMC has the following Specific Objectives: (1) perform scientific peer review of cancer-related clinical and translational research protocols to be conducted at UCSD, at affiliate institutions Rady Children's Hospital San Diego (RCHSD) and the Veterans Affairs San Diego Healthcare System (VASDHS), and to be conducted by consortium partner San Diego State University (SDSU);(2) approve a priority designation for new interventional cancer clinical protocols in coordination with leaders of the Cancer Center's multidisciplinary Disease Teams;and (3) review the scientific progress of active interventional protocols through annual evaluation of subject accrual data. The PRMC is granted authority by the Cancer Center Director to approve, defer, or disapprove the activation of research protocols that involve patients with cancer, biological specimens from cancer patients, or subjects that are at significant risk to develop cancer during the study period. The PRMC can issue binding recommendations for protocol modification or amendment for reasons of scientific validity or subject safety and issue recommendations to the Director of the Clinical Trials Office (CTO) for closure of protocols with unsatisfactory accrual or for changes in scientific knowledge. In concert with these scientific review and monitoring functions, the PRMC directly informs the Institutional Review Boards of relevant scientific and participant safety issues for complementary review of cancer-related research protocols. PRMC membership is composed of clinical and basic scientists as well as biostatisticians with expertise to perform unbiased evaluations of cancer protocols submitted for PRMC review and monitoring. In achieving its scientific review and monitoring objectives, the PRMC ensures that Cancer Center resources are effectively utilized to foster clinical cancer research that is of high scientific quality and importance.

Public Health Relevance

The specialized clinical, scientific, and pharmacy expertise of the Protocol Review and Monitoring Committee is brought to bear in evaluating the supporting data and rationale for investigational cancer therapies and the adequacy of monitoring for toxicities. Review of scientific validity, value, and feasibility promote the Cancer Center's mission to develop novel therapies and provide access to leading-edge care for patients with cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
La Jolla
United States
Zip Code
Sen, Supriya; Langiewicz, Magda; Jumaa, Hassan et al. (2015) Deletion of serine/arginine-rich splicing factor 3 in hepatocytes predisposes to hepatocellular carcinoma in mice. Hepatology 61:171-83
Hoffmann, Hanne M; Tamrazian, Anika; Xie, Huimin et al. (2014) Heterozygous deletion of ventral anterior homeobox (vax1) causes subfertility in mice. Endocrinology 155:4043-53
Hartman, Lisa L R; Crawford, John R; Makale, Milan T et al. (2014) Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol 36:451-7
Williams, Richard T; Barnhill, Lisa M; Kuo, Huan-Hsien et al. (2014) Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth. PLoS One 9:e88219
Huang, Carlos P; Fofana, Mariama; Chan, Jefferson et al. (2014) Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin. Metallomics 6:654-61
Paolini, Paul; Pick, Daniel; Lapira, Jennifer et al. (2014) Developmental and extracellular matrix-remodeling processes in rosiglitazone-exposed neonatal rat cardiomyocytes. Pharmacogenomics 15:759-74
Goellner, Eva M; Smith, Catherine E; Campbell, Christopher S et al. (2014) PCNA and Msh2-Msh6 activate an Mlh1-Pms1 endonuclease pathway required for Exo1-independent mismatch repair. Mol Cell 55:291-304
Glidewell-Kenney, Christine A; Trang, Crystal; Shao, Paul P et al. (2014) Neurokinin B induces c-fos transcription via protein kinase C and activation of serum response factor and Elk-1 in immortalized GnRH neurons. Endocrinology 155:3909-19
Jiang, P; Mukthavaram, R; Chao, Y et al. (2014) In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br J Cancer 111:1562-71
Jacques, Bonnie E; Montgomery 4th, William H; Uribe, Phillip M et al. (2014) The role of Wnt/*-catenin signaling in proliferation and regeneration of the developing basilar papilla and lateral line. Dev Neurobiol 74:438-56

Showing the most recent 10 out of 359 publications